CONSULTANTS

---

Dr Mark Nicolls is associate Dean of Research at Stanford Medical School, the Stanford Professor and Endowed Chair of Pulmonary and Critical Care Medicine, and Chief of the Pulmonary, Allergy and Critical Care Medicine Division at Stanford University. He is also the Director of Lung Immunology at Stanford, a member of the Stanford Institute of Immunity, Transplantation, and Immunology, a board member for the Wall Center for Pulmonary Vascular Research, as well as the Cardiovascular Institute at Stanford University. Dr Nicolls has a joint appointment with Immunology and Rheumatology at Stanford. His lab focuses on the interaction between immune system and vasculature as it pertains to lymphedema, pulmonary hypertension, lung transplantation, and emphysema. He has >25 years of experience working in immunology, creating the first non-lytic anti-CD3 monoclonal antibody as a tolerizing transplant immunotherapy. He was a member of Bruce Hall’s team at Stanford in the early 1990s when Tregs were first characterized by his group and have continued since that time to perform research on immune regulation and vascular disorders. His most recent projects focus on the role of immune dysregulation in the evolution of lymphedema 1 and pulmonary hypertension 2, as well as why preserving microvascular health may prevent chronic rejection in solid organ transplant recipients 3. On the clinical side, he cares for lung transplant patients, Co-Chaired the 1st Aspen Lung Conference focused on lung transplantation, and was the Co-Chair, communicating, and senior author for the NHLBI Consortium and Consensus Statement on pre-clinical models in lung transplantation. Dr Nicolls led an NIH-funded multicenter trial with 26 participating sites focused on B cell depletion for the treatment of systemic sclerosis-associated pulmonary hypertension 4. He is also the communicating PI for a recent NIH lung transplant consortium U01 award to study immune responses in lung transplant recipients. Dr Nicolls has been a PI on a K12 training grant, and he is communicating PI for the Pulmonary Biology T32 and he is dedicated to the training of clinician-scientists.

  Dr. Charlie Strange is Professor of Pulmonary, Critical Care, Allergy, and Sleep Medicine at the Medical University of South Carolina in Charleston.  He is an expert in clinical trial design in rare diseases and is a past NIH recipient in sarcoidosis clinical trials.  As an actively practicing physician, he will assist with protocol design, investigational new drug applications, study feasibility, and outcome measures for studies in sarcoidosis.